University Of California, San Francisco

Three prominent clinical trials testing Paxlovid and monoclonal antibodies for Long COVID failed to show significant health improvements compared to placebo groups.

The progressive supranuclear palsy (PSP) market is experiencing significant growth driven by emerging therapies including AZP2006 and AMX0035, which are advancing through clinical trials with promising results.

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.

Invivyd has established the SPEAR Study Group with leading researchers to investigate monoclonal antibody therapy for Long COVID and Post-Vaccination Syndrome, following anecdotal reports of symptom relief with PEMGARDA.

A multinational study demonstrates that AI assistance significantly improves pathologists' accuracy in HER2 breast cancer scoring, with accuracy rates increasing from 89.1% to 96.1% when AI tools were utilized.

A retrospective analysis by Mass General Brigham and UCSF researchers found that glioblastoma patients taking gabapentin lived 4-6 months longer than those who didn't receive the medication.

The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health.

A new JAMA Network Open study reveals that while most OB/GYNs didn't immediately leave states with abortion bans after the 2022 Dobbs ruling, a significant decline is now occurring in the 12 most restrictive states.

New research shows that complete blood count (CBC) tests can identify or predict multiple diseases including heart problems, type 2 diabetes, osteoporosis, and kidney disease by analyzing individual "set points" in blood components.

FG-3246, a first-in-class antibody-drug conjugate targeting CD46, demonstrated an 80% disease control rate and 20% objective response rate in heavily pre-treated metastatic castration-resistant prostate cancer patients.